{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:23:12Z","timestamp":1771464192703,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40618-019-01077-8","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T17:03:03Z","timestamp":1563296583000},"page":"57-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The treatment with pasireotide in Cushing\u2019s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center"],"prefix":"10.1007","volume":"43","author":[{"given":"C.","family":"Simeoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Iacuaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Angellotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Negri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"issue":"4","key":"1077_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36(4):385\u2013486","journal-title":"Endocr Rev"},{"issue":"7","key":"1077_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4(7):611\u2013629","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9522","key":"1077_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing\u2019s syndrome. Lancet 367(9522):1605\u20131617 (review)","journal-title":"Lancet"},{"issue":"2","key":"1077_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ecl.2005.01.010","volume":"34","author":"R Pivonello","year":"2005","unstructured":"Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome. Endocrinol Metab Clin N Am 34(2):327\u2013339 (viii, review)","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"12","key":"1077_CR5","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 88(12):5593\u20135602 (review)","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1077_CR6","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1077_CR7","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807\u20132831","journal-title":"J Clin Endocrinol Metab"},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40618-015-0353-0","volume":"39","author":"LG Perez-Rivas","year":"2016","unstructured":"Perez-Rivas LG, Reincke M (2016) Genetics of Cushing\u2019s disease: an update. J Endocrinol Invest 39:29\u201335","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1077_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukuhara N, Okada M, Nishioka H, Takeuchi Y, Komada M, Takeshita A, Yamada S (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol 174(2):213\u2013226","journal-title":"Eur J Endocrinol"},{"key":"1077_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 366:32\u201342","journal-title":"N Engl J Med."},{"issue":"3","key":"1077_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81(3):408\u2013417","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1077_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R, Pasireotide B2305 Study Group (2015) Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18(5):604\u2013612","journal-title":"Pituitary"},{"issue":"3","key":"1077_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12020-015-0557-2","volume":"50","author":"C Simeoli","year":"2015","unstructured":"Simeoli C, Auriemma RS, Tortora F, De Leo M, Iacuaniello D, Cozzolino A, De Martino MC, Pivonello C, Mainolfi CG, Rossi R, Cirillo S, Colao A, Pivonello R (2015) The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine 50(3):725\u2013740","journal-title":"Endocrine"},{"issue":"1","key":"1077_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","volume":"39","author":"Y Reznik","year":"2013","unstructured":"Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verg\u00e8s B (2013) Management of hyperglycemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide. Diabetes Metab 39(1):34\u201341 (review)","journal-title":"Diabetes Metab"},{"issue":"2","key":"1077_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180\u2013186 (review)","journal-title":"Pituitary"},{"issue":"9491","key":"1077_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome a new worldwide definition. Lancet 366(9491):1059\u20131062","journal-title":"Lancet"},{"key":"1077_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB (2014) Clinical practice guideline for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 16:14\u201326","journal-title":"J Clin Hypertens"},{"issue":"25","key":"1077_CR18","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143\u20133421 (PMID: 12485966)","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1077_CR19","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes 2018. Diabetes Care 41(Suppl 1):S13\u2013S27","journal-title":"Diabetes Care"},{"key":"1077_CR20","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). \nhttp:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"1077_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1077_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM (2014) Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17(4):320\u2013326","journal-title":"Pituitary"},{"key":"1077_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","volume":"57","author":"S Petersenn","year":"2017","unstructured":"Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BM (2017) Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57:156\u2013165","journal-title":"Endocrine"},{"issue":"4","key":"1077_CR24","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.4158\/EP12296.CR","volume":"19","author":"L Lu","year":"2013","unstructured":"Lu L, Duan L, Jin Z, Lu Z, Gu F (2013) Effective long-term treatment of Cushing\u2019s disease with pasireotide: a case report. Endocr Pract. 19(4):e92\u2013e96","journal-title":"Endocr Pract."},{"key":"1077_CR25","first-page":"735489","volume":"2013","author":"C Yedinak","year":"2013","unstructured":"Yedinak C, Brzana J, Fleseriu M (2013) Monitoring patient improvement parameters following pasireotide treatment in Cushing\u2019s disease. Case Rep Endocrinol 2013:735489","journal-title":"Case Rep Endocrinol"},{"issue":"3","key":"1077_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","volume":"18","author":"L Trementino","year":"2014","unstructured":"Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2014) Up-to 5-year efficacy of\u00a0pasireotide\u00a0in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18(3):359\u2013365","journal-title":"Pituitary"},{"issue":"5","key":"1077_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/s-0042-101347","volume":"48","author":"L Trementino","year":"2016","unstructured":"Trementino L, Michetti G, Angeletti A, Marcelli G, Concettoni C, Cardinaletti C, Polenta B, Boscaro M, Arnaldi G (2016) A single-center 10-year experience with pasireotide in Cushing\u2019s disease: patients\u2019 characteristics and outcome. Horm Metab Res 48(5):290\u2013298","journal-title":"Horm Metab Res"},{"issue":"6","key":"1077_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","volume":"17","author":"J Mackenzie Feder","year":"2014","unstructured":"Mackenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2014) Pasireotide monotherapy in Cushing\u2019s disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17(6):519\u2013529","journal-title":"Pituitary"},{"issue":"8","key":"1077_CR29","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ccr3.321","volume":"3","author":"E Grossrubatscher","year":"2015","unstructured":"Grossrubatscher E, Zampetti B, Dalino Ciaramella P, Doneda P, Loli P (2015) Effectiveness of low-dose pasireotide in a patient with Cushing\u2019s disease: antiproliferative effect and predictivity of a short pasireotide suppression test. Clin Case Rep 3(8):718\u2013722","journal-title":"Clin Case Rep"},{"issue":"2","key":"1077_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2265.2008.03486.x","volume":"71","author":"K Cukier","year":"2009","unstructured":"Cukier K, Tewari R, Kurth F, Schmid HA, Lai C, Torpy DJ (2009) Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing\u2019s disease. Clin Endocrinol (Oxf) 71(2):305\u2013307","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1077_CR31","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1077_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","volume":"103","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Hermosillo Res\u00e9ndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103(3):458\u2013465","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"1077_CR33","first-page":"425","volume":"17","author":"F Ceccato","year":"2015","unstructured":"Ceccato F, Scaroni C, Boscaro M (2015) Clinical use of pasireotide for Cushing\u2019s disease in adults. Ther Clin Risk Manag 17(11):425\u2013434","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"1077_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12020-015-0754-z","volume":"50","author":"S Petersenn","year":"2015","unstructured":"Petersenn S (2015) How to manage pasireotide, when using as medical treatment for Cushing\u2019s disease. Endocrine 50(3):526\u2013528","journal-title":"Endocrine"},{"issue":"7","key":"1077_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1517\/21678707.2013.807731","volume":"1","author":"A Colao","year":"2013","unstructured":"Colao A, Simeoli C, De Leo M, Cozzolino A, Pivonello R (2013) Pasireotide for the treatment of Cushing\u2019s disease. Expert Opin Orphan Drugs 1(7):557\u2013567. \nhttps:\/\/doi.org\/10.1517\/21678707.2013.807731","journal-title":"Expert Opin Orphan Drugs"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01077-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01077-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01077-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T23:13:48Z","timestamp":1594768428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01077-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01077-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"12 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.S. has been occasional consultant for Shire and Ipsen. R.F., M.C.D.M., D.I., F.P., D.A., C.P., Ro.Pa., and M.N. have nothing to disclose. A.C. has been Principal Investigator of Research Studies for Novartis, Ipsen, and Pfizer; received research grants from Novartis. Ro.Pi. has been Principal Investigator of Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring and Italfarmaco; and has received fees and honoraria for presentations from Novartis, Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}